



Comprehensive Review on Versatile Nature of Curcumin and it's Pharmacological Activities

¹Vaibhav Raut*, ²Nayana Navsupe, ³Vrushali Pathak, ⁴Shashikant Bhandari, ⁵Shital Patil

Student^{1, 2, 3}, Professor⁴, Assistant Professor⁵

¹Department of Pharmaceutical Chemistry,

¹All India Shri Shivaji Memorial Society's College of Pharmacy, Kennedy Road, Near R.T.O., Pune-411001, M.S., India.

Abstract

Many natural medicinal plants have been utilised to cure a range of disorders since ancient times and are regarded as a possible source of phytochemicals for the creation of new medications. One of these is curcumin, a bioactive molecule that is easily available, affordable, and harmless. It is a vital, naturally occurring, highly lipophilic and phenolic chemical. Curcumin (diferuloylmethane), a low-molecular-weight chemical derived from the roots of *Curcuma longa* L. (family Zingiberaceae), is mostly used as a curry spice, flavouring agent, insect repellent, food colouring agent, traditional medication, and cosmetic component. Curcumin is a tautomeric molecule that exists in organic solvents as an enolic form and in water as a keto form. Though inconclusive, epidemiological findings show that turmeric intake may lessen the incidence of some malignancies and provide other beneficial biological benefits in people. Turmeric's biological benefits have been linked to its ingredient curcumin, which has been extensively researched for its anti-inflammatory, anti-ulcer, anti-diabetic, anti-viral, antioxidant, wound healing, and anti-cancer properties. Curcumin is a low-toxicity nutraceutical that has been utilised successfully in a variety of medical ailments, as discussed in this article.

Keywords

Curcumin, pharmacological activities, turmeric, structure activity relationship, molecular targets

I. Introduction

Since ancient times, humans have used herbs and plants to heal a variety of ailments^{1,2}. Plants have been utilised for numerous reasons throughout human history, and evidence supporting the use of herbal medicine continues to grow. Traditional and indigenous medicines are currently receiving a lot of interest from researchers all around the world because of their great therapeutic potential and lack of known or reported negative effects. Curcumin is a well-known, lucrative, and vital traditional plant ingredient. Curcumin (diferuloylmethane), a polyphenolic molecule isolated from the rhizomes of *Curcuma longa* L. and related species, is the natural yellow colour in the roots of turmeric (family Zingiberaceae). Curcumin's chemical name is 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, and it is water insoluble. Curcumin is fragrant, having a faint orange and ginger scent, yet it has a bitter taste³. It accounts for around 4% of the drug's dry weight⁴. Maceration, microwave treatment, digestion, infusion, and Soxhlet extraction procedures have all been utilised to extract curcumin from turmeric. When all of the published techniques are compared, Soxhlet extraction comes out on top. Curcumin may be extracted in huge quantities with less solvent, saving time, money, and energy⁵.

Turmeric has a carbohydrate content of 69.4 %, 13.1 % water, 6.3 % protein, 5.1 % fat, and 3.5 % minerals^{6,7}. Turmeric fractions are known as curcuminoids. Curcuminoids make up commercial curcumin, which contains

around 77 % curcumin (curcumin I), 18 % demethoxycurcumin (curcumin II), 5 % bisdemethoxycurcumin (curcumin III), and cyclocurcumin (curcumin IV)⁸. Other components of raw turmeric include tumerone, zingiberone, atlantone, carbohydrates, proteins, and resins, as well as numerous volatile oils including tumerone, zingiberone, and atlantone. Turmeric has been used as a culinary spice in curry for ages in numerous Asian nations to give it its distinct flavour and colour. Turmeric has also established itself as an important folk medicinal herb with reported therapeutic properties for a variety of ailments and diseases, including inflammation and infection. It's also used as a tonic and "blood purifier," as well as a topical ointment, in bath soaps, and to heal cuts, bruises, and sprains. Because of its high pharmacological actions and health advantages, curcumin has long been regarded one of the most well investigated natural compounds. In this article, we go through the chemistry of curcumin and how it may be used to treat a variety of disorders, as seen in Fig.1.




Figure 1 Role of curcumin in different disease.

II. Chemistry and Structure Activity Relationship (SAR) of curcumin

Curcumin was extracted from the medicine for the first time in 1815, but its structure wasn't discovered until 1913. Curcumin's naturally occurring curcuminoids ratios are around 5% bisdemethoxycurcumin, 15% demethoxycurcumin, and 80% curcumin. Figure 2 Curcumin is insoluble in water while soluble in ethanol and acetone. The most essential active element responsible for turmeric's biological action is curcumin [1, 7-bis (hydroxyl-3-methoxyphenyl)-1,6- heptadiene-3, 5-dione] (C₂₁H₂₀O₆). Curcumin is relatively unstable in phosphate buffer at pH 7.4, and its stability is greatly enhanced by reducing the pH or adding glutathione, N-acetyl cysteine, ascorbic acid, or rat liver microsomes⁹.






Figure 2 Major curcuminoids responsible for the composition of turmeric

Curcumin is a bis- α,β -unsaturated β -diketone that occurs in equilibrium in both the keto and enol forms as in Fig.3. It has been discovered that the keto form predominates in neutral and acidic settings, whereas the enolic form predominates in alkaline circumstances.




Figure 3 Keto-enol tautomerism in curcumin

Curcumin's structure shows that it is made up of two phenyl rings joined by a seven-carbon keto-enol linker and replaced with hydroxyl and methoxy groups (C7). While curcumin is sourced from nature, its derivatives are usually made by a chemical process involving aryl-aldehydes and acetylacetone. This type of assembly can produce a variety of chemical analogues, such as molecules containing alkyl substituents on the linker's middle carbon (C7 moiety)^{10,11}. The presence of a coplanar hydrogen donor group and α -diketone moiety is required for antiandrogenic action in the treatment of prostate cancer, according to a SAR investigation of curcumin derivatives, and reducing the linker from seven carbon atoms (C7) to five carbon atoms (C5) promotes antiandrogenic activity¹². The benzyl rings are especially important for tumour growth inhibition, and adding hydrophobic substituents to them (R1, R2, R3, R4 in) has been associated to improved anticancer efficacy of curcumin derivatives^{13,14}. O-methoxy substitution was found to be more effective in suppressing nuclear factor κ -light-chain-enhancer of activated B cells (NF- κ B), but this modification has also affected the lipophilicity of curcumin¹⁵. A summary of the potential sites of modification on the curcumin molecule is illustrated in Fig.4.




Figure 4 The Main pharmacophores and potential substitution position.

III. MULTIPLE MOLECULAR TARGETS

Extensive evidence suggests that curcumin interacts with a wide range of molecular targets, including transcription factors, growth factors, cytokines, kinases, enzymes, receptors, and different proteins that regulate cell proliferation and death (Fig.5). Curcumin has direct interactions with cyclooxygenase-2 (COX-2), DNA polymerase, lipoxygenase (LOX), and glycogen synthase kinase-3 (GSK-3) and an autophosphorylation-activated protein kinase. It interacts with a number of transcription factors indirectly, including nuclear factor NF- κ -B (NF- κ B), activator protein 1 (AP-1), catenin, signal transducer and activator of transcription (STAT) proteins, and peroxisome proliferator-activated receptor (PPAR). Curcumin has been shown to inhibit the function of several growth factors, including epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF-), and other proteins involved in growth signalling and cell proliferation. There is evidence that curcumin-induced apoptosis is linked to lower expression of proapoptotic proteins, vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 1 (VEGFR-1). Curcumin completely inhibits the activity of a variety of protein kinases, including EGF receptor (EGFR) kinase, endoplasmic reticulum kinase, protein kinase A (PKA), protein kinase B (PKB), protein kinase C (PKC), and Janus kinase (JAK), while activating mitogen-activated protein kinases (MAPK). Curcumin inhibits cell cycle progression in many types of tumor cells. It has been shown to arrest the cell cycle at the G0/G1 or G2/M phase transitions by upregulating cyclin-dependent kinase inhibitors (e.g., p21, p27) and tumour suppressor p53, while downregulating G2/mitotic-specific cyclin-B1 and cell division control protein 2 homolog (encoded by CDC2) in immortalised human umbilical vein endothelial (ECV304) cells. Curcumin-induced apoptosis is also related with caspase-8 activation, Bcl-2 homology domain 3 (BH3)-interacting domain death agonist (BID) cleavage, Bcl-2-like protein 1 (Bcl2-L-1), cytochrome c release, caspase-9 and caspase-3 activation, and PARP cleavage¹⁶⁻¹⁸. Curcumin's capacity to mediate several molecular targets, as well as its benign nature, making it an excellent therapeutic medication for a variety of chronic disorders.









Figure 5 Molecular targets for Curcumin.

IV. Versatile activities of Curcumin

Turmeric has long been ingested by the people of India and other subcontinent regions, not just in food but also in the treatment of a wide range of maladies, with no known negative effects. Curcumin is the active ingredient in turmeric (diferuloylmethane). Curcumin has lately piqued the interest of chemists due to its broad spectrum of possible medicinal uses for a wide range of ailments. As seen in Table 1, chemical changes to curcumin exhibit varying levels of activity. In the next sections, we discuss curcumin's possibly major significance as a possible therapeutic agent in several illness conditions.

Table 1 Pharmacological activity of curcumin derivatives.

Sr.No	Curcumin derivatives	Chemical structure	Chemical modification	Activity
1	Tetrahydrocurcumin (THC)		Hydrogenated diketone moiety	Enhanced antioxidant activity
2	Gallium, vanadium, and indium complexes		Metal complexation by the β -diketones	Enhanced cytotoxic activity
3	Dimethyl curcumin		Methyl groups substitution on R ₂ and R ₄	Enhanced activity toward prostate and breast cancer
4	Hydrazinocurcumin		Replacing the diketone moiety with hydrazine derivative	Higher efficacy in inhibition of colon cancer progression via antagonism of Ca ²⁺ /CaM function
5	Curcumin carbocyclic analogues		Introducing carboxyl group at the diketone moiety	Enhanced antioxidant activity and stronger inhibition of HIV d 1 protease

4.1 Antioxidant activity

Curcumin has been found in several studies to be effective at scavenging superoxide radicals, hydrogen peroxide, and nitric oxide (NO) from activated macrophages, as well as decreasing iron complexes and preventing lipid peroxidation¹⁹. These acts might be the primary mechanism by which curcumin exerts its pharmacological / therapeutic effects²¹. Curcumin therapy has also been shown to reduce lipid peroxidation and oxidative stress caused by smoking²¹. Curcumin has been demonstrated to protect renal cells and brain glial cells from oxidative damage²². Curcumin has also been shown to boost the activity of other anti-oxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase. Curcumin also protects endothelial cells from oxidative stress by inducing haem oxygenase-1²³. Curcumin at a concentration of 0.1 percent was fed to retinol-deficient rats for three weeks and reduced the degree of lipid peroxidation in their tissues²⁴. Curcumin's anti-oxidant properties can protect tissues against the effects of oxidative stress caused by radiation (REF), metals, and severe skeletal muscle damage²⁵. Its antioxidant activity is mostly attributed to the phenolic hydroxyl group, which scavenges free radicals by donating its H (electron) atom.

4.2 Antiulcer Activities

Ali et al.²⁶ developed and characterized mucoadhesive microspheres of curcumin for the potential use of treating gastric adenocarcinoma, gastric and duodenal ulcer associated with *Helicobacter pylori*. The drug released from the optimized formulation showed a controlled-release pattern that offered both local and systemic action for effective treatment of *H. pylori* infection. Li et al.²⁷ studied curcumin–piperine mixtures in self microemulsifying drug delivery systems (SMEDDS) for the treatment of ulcerative colitis. For in vivo studies, mice were used to test its therapeutic effectiveness against ulcerative colitis. Acute ulcerative colitis was induced by the oral administration of 5% dextran sulfate sodium (DSS) ad libitum for seven consecutive days. They measured the severity of clinical symptoms by assessing the body weight loss, stool consistency and stool blood, and finally, they evaluated the therapeutic effects of curcumin–piperine SMEDDS treatment.

Their findings demonstrated that curcumin–piperine SMEDDS treatment significantly suppressed DSS-induced colitis in mice by improving their body weight and stool consistency as well as decreasing intestinal bleeding.

4.3 Antidiabetic activity

Curcumin has shown to be effective against various causative factors of diabetes mellitus and its associated complications. Joshi et al.²⁸ increased the effectiveness of curcumin by introducing a self-nanoemulsifying drug delivery system (SNEDDS) for curcumin to enhance its bioavailability and then evaluated its efficacy in experimental diabetic neuropathy and found that it has significant therapeutic potential for the treatment of various diabetes complications. Steigerwalt et al.²⁹ evaluated the improvement of diabetic angiopathy and retinopathy with curcumin. They administered curcumin at the dosage of 2 tablets/day (each tablet containing 500 mg curcumin phospholipid, corresponding to 100 mg curcumin) for at least 4 weeks. These observations indicated the potential value of curcumin in the management of diabetes-associated peripheral microangiopathy and retinopathy³⁰.

4.4 Antimalarial activity

Malaria has long been a major global health problem, as it is the most common parasite illness and the leading cause of illness and mortality worldwide. Curcumin has been proven in several studies to have antimalarial action both in vitro and in vivo^{31–33}. Curcumin and an ethanolic extract of *Curcuma longa* have been shown to have significant in vitro inhibitory effectiveness against *Plasmodium falciparum*, *Leishmania major*, *Coccidia*, and *Trypanosoma* species^{34–36}. Curcumin's leishmanicidal activity has also been demonstrated in vitro³⁷. Curcumin has recently been found to be beneficial in the treatment of malaria³⁸.

4.5 Wound Healing activity

Wounding or physical strain are the most common causes of skin injury. Skin injury triggers a complex and well-orchestrated healing process that culminates in the complete restoration of the integrity of damaged tissue and the restoration of this functional barrier^{39–41}. Complete healing takes a long time in situations of serious injury. As a result, several research on wound dressings that improve wound healing and reduce scar formation have been conducted. Curcumin research suggests that it may heal wounds and reduce the likelihood of scar formation more efficiently than other synthetic medicinal substances^{42–44}.

4.6 Anti-viral activity

Several in vivo and in vitro investigations have shown that curcumin has moderate to high inhibitory action against some viruses such as human simple-virus-2^{45,46} and type I HIV⁴⁷. Curcumin had no effect on HIV-1 proliferation in acutely infected MT-4 cells⁴⁸. Two curcumin analogues, dicaffeolymethan and rosmarinic acid, have been found to have more antiviral action than curcumin⁴⁹. Curcumin has been demonstrated to be effective in reducing P24 antigen production in cells infected with HIV-1, whether acutely or persistently⁵⁰, and also suppressing HIK 1 integrase enzymatic activities but not in other viral (HIV-1 reverse transcriptase) or cellular (RNA polymerase II) nucleic acid processing enzymes⁵¹.

4.7 Anti-Alzheimer's activity

Because of the anti-inflammatory and anti-oxidant actions of curcumin, it was tested against Alzheimer's disease⁵². An alternative mechanism of these effects is metal chelation, which may reduce amyloid aggregation or oxidative neurotoxicity. Metals can induce beta aggregation and toxicity, and are concentrated in Alzheimer's disease brain. The chelators desferrioxamine and clioquinol have exhibited anti- Alzheimer's disease effects⁵³. Review of Tang et al include the mechanism of phytochemicals (curcumin) in Alzheimer's disease⁵⁴.

4.8 Anti-inflammatory activity

Curcumin was shown to be more efficient than hydrocortisone at inhibiting leukotriene production in rat peritoneal polymorphonuclear neutrophils. [1-8,9]

Curcumin protected rats from urethral occlusion-induced renal interstitial inflammation and fibrosis. Inhibition of the NF-kappaB-dependent pathway is engaged in the processes, however AP-1 inhibition is unlikely to be implicated in curcumin's positive effects⁵⁵.

Huang et al⁵⁶ showed that curcumin inhibits proliferation of blood mononuclear cells and vascular smooth muscle cells. Curcumin, according to the authors, might be employed clinically in transplant atherosclerosis. Curcumin has been demonstrated to block IL-1stimulated gene expression of a neutrophil chemotactic

peptide, interleukin-8 (IL-8), as well as lipopolysaccharide-induced IL-1 and TNF production by a human monocyte protein macrophage cell line^{57,58}. In addition, curcumin has been shown to inhibit the proinflammatory I Th1 cytokine profile⁵⁹, and NF-kappaB activation pathway^{60,61}.

Curcumin also suppresses MMP overexpression, presumably due to its ability to inhibit protein kinase C⁶².

4.9 Anticancer activity

Carcinogenesis is a three-stage process that comprises of three distinct but interconnected stages: initiation, promotion, and progression. The promotion of cancer is aided by oxidative and inflammatory tissue damage. Curcumin, as an anti-inflammatory and anti-oxidant substance, has the potential to prevent cancer by reducing tumour promotion. It also slows cell development and promotes apoptosis in a variety of cell types. Curcumin interacts with a variety of cell regulatory proteins, including the MAP cascade. It inhibits v-Src directly, resulting in decreased phosphorylation of Src, cortactin, and focal adhesion kinase (FAK). Curcumin also directly inhibits the activity of FAK. This results in a lack of Src-mediated cell motility, which has crucial consequences for invasion and metastasis. Bone inflammation and cancer are both disorders that cause bone resorption to rise. Curcumin has been shown to promote cell death and decrease bone resorption. As a result, it has been proposed for usage in cases of bone inflammation and malignancy.

V. Toxicological properties of curcumin

Curcumin is known to be non-toxic in both humans and animals. Adults in India are estimated to consume 80–200 mg of curcumin each day⁶³. Except for a few occurrences of contact dermatitis, there have been no reports of side effects from curcumin or its equivalents⁶⁴. In a phase 1 clinical research involving 25 volunteers, treatment of up to 8000 mg of curcumin per day for three months resulted in no detectable toxicity. Five more clinical trials in which individuals were administered 1125–2500 mg curcumin per day validated the substance's apparent safety. Turmeric may have an antiplatelet activity⁶⁵, and its concurrent use with anticoagulants may lead to an additive effect. Although there have been no instances of this in humans, it should be avoided in individuals with bleeding problems and bile duct blockage, and should only be used in individuals with gallstones under the guidance of a physician. According to the literature, curcumin has no harmful effects. Curcumin has also been pronounced safe and well tolerated by the US Food and Drug Administration⁶⁶, even at dosages of 8 g/day for 3 months and 12 g/day for 3 to 4 months^{67–71}.

VI. Limitations of Curcumin

Despite curcumin's diverse pharmacological potential, its use has some serious drawbacks, including poor water solubility, low oral bioavailability, poor absorption from the gastrointestinal (GI) tract, rapid clearance from the body, and degradation at alkaline pH, which reduces its bioavailability and absorption in the preintestinal region, resulting in a reduction in the drug's dose^{72–75}. Curcumin has a fast metabolic rate and a short biological half-life. It has a low physicochemical stability.

VII. Conclusion

Curcumin has been widely utilised for its numerous health advantages all over the world. It may also aid in the control of multiplication of Pharmacological activity in health, as well as enhance the health for bodily advantages for human health, hence increasing recuperation and subsequent performance in active individuals. Curcumin is a nutraceutical ingredient featuring diverse pharmacological properties, some of which have been studied and tested in both humans and animals. The study discussed in the preceding sections emphasise the important function of curcumin in the treatment and even cure of many illnesses. Furthermore, the findings reported here show that using curcumin at large dosages for long periods of time is quite safe and nontoxic. Overall, our findings show that curcumin has significant medicinal value and scope in future.

References

1. Chotchoungchatchai S, Saralamp P, Jenjittikul T, Pornsiripongse S. Medicinal plants used with Thai Traditional Medicine in modern healthcare services : A case study in Kabchoeng Hospital , Surin Province , Thailand. *J Ethnopharmacol.* 2012;141(1):193-205. doi:10.1016/j.jep.2012.02.019
2. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “ Curecumin ”: From kitchen to clinic. 2008;75:787-809. doi:10.1016/j.bcp.2007.08.016
3. Lal J. Turmeric , Curcumin and Our Life : A Review. 2012;1(June):11-17.
4. Eigner D, Scholz D. treatment and diet in Nepal. 1999;67:1-6.
5. Communication IC, Nabati M, Mahkam M, Heidari H. Isolation and characterization of curcumin from powdered rhizomes of turmeric plant marketed in Maragheh city of Iran with soxhlet technique. 2014;2:236-243.
6. Bagchi A. Extraction of Curcumin. 2012;1(3):1-16.
7. Heffernan C, Ukrainczyk M, Gamidi RK, Hodnett BK, Rasmuson ÅC. Extraction and Purification of Curcuminoids from Crude Curcumin by a Combination of Crystallization and Chromatography. Published online 2017.
8. Esatbeyoglu T, Huebbe P, Ernst IMA, Chin D, Wagner AE, Rimbach G. Curcumin — From Molecule to Biological Function *Angewandte*. Published online 2012;2-27. doi:10.1002/anie.201107724
9. Commandeur JNM, Samhoedi R, Vermeuk NPE. Effects of Curcumin on Cytochrome P450 and Glutathione S-Transferase Activities in Rat Liver. 1996;51(95):39-45.
10. Chen W, Deng S, Zhou B, Yang L, Liu Z. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation : H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. 2006;40:526-535. doi:10.1016/j.freeradbiomed.2005.09.008
11. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang H, Itokawa H. Antitumor Agents . 217 . † Curcumin Analogues as Novel Androgen Receptor Antagonists with Potential as Anti-Prostate Cancer Agents. Published online 2002:5037-5042.
12. Lin L, Shi Q, Su C, Shih C, Lee K. Antitumor agents 247 . New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents q. 2006;14:2527-2534. doi:10.1016/j.bmc.2005.11.034
13. Xu G, Chu Y, Jiang N, Yang J, Li F. The Three Dimensional Quantitative Structure Activity Relationships (3D-QSAR) and Docking Studies of Curcumin Derivatives as Androgen Receptor Antagonists. Published online 2012:6138-6155. doi:10.3390/ijms13056138
14. Yadav B, Taurin S, Rosengren RJ, et al. Bioorganic & Medicinal Chemistry Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. *Bioorg Med Chem.* 2010;18(18):6701-6707. doi:10.1016/j.bmc.2010.07.063
15. Sandur SK, Pandey MK, Sung B, et al. turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. 2007;28(8):1765-1773. doi:10.1093/carcin/bgm123
16. Kasi PD, Tamilselvam R, Skalicka-wo K, et al. Molecular targets of curcumin for cancer therapy : an updated review. Published online 2016:13017-13028. doi:10.1007/s13277-016-5183-y
17. Xue X, Yu J, Sun D, et al. Curcumin as a multidrug resistance modulator — A quick review. *Biomed Prev Nutr.* 2013;3(2):173-176. doi:10.1016/j.bionut.2012.12.001
18. Ravindran J, Prasad S, Aggarwal BB. Curcumin and Cancer Cells : How Many Ways Can Curry Kill Tumor Cells Selectively ? 2009;11(3). doi:10.1208/s12248-009-9128-x
19. Tilak JC, Banerjee M, Mohan H, Devasagayam TPA. Antioxidant Availability of Turmeric in Relation to its Medicinal and Culinary Uses. 2004;804(January):798-804.
20. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. 2000;71:23-43.
21. Turmeric EOF. Original Contribution. 1998;24(1):49-54.
22. Of E, Turmeric D, Lipid ONI, In P, Liver RAT. (curcuma longa). 1994;32(3):279-283.
23. Antioxidant AN, Agent A. Fast Track Paper. 2000;28(8):1303-1312.
24. Kaul S, Krishnakantha TP. Influence of retinol deficiency and curcumin / turmeric feeding on tissue microsomal membrane lipid peroxidation and fatty acids in rats. Published online 1997:43-48.
25. Vignaud A, Cebrian J, Martelly I, Caruelle J, Ferry A. Effect of anti-inflammatory and antioxidant drugs on the long-term repair of severely injured mouse skeletal muscle. Published online 2005:487-495. doi:10.1113/expphysiol.2005.029835
26. Sciences ML. Review Curcumin: From ancient medicine to current clinical trials. 2008;65:1631-1652. doi:10.1007/s00018-008-7452-4
27. Sharma RA, Steward WP, Gescher AJ. PHARMACOKINETICS AND PHARMACODYNAMICS OF

CURCUMIN.

28. Ji H, Shen L. Can improving bioavailability improve the bioactivity of curcumin? *Trends Pharmacol Sci*. Published online 2014:1-2. doi:10.1016/j.tips.2014.04.001
29. Amalraj A, Pius A, Gopi S, Gopi S. Journal of Traditional and Complementary Medicine Biological activities of curcuminoids , other biomolecules from turmeric and their derivatives e A review. *J Tradit Chinese Med Sci*. Published online 2016. doi:10.1016/j.jtcme.2016.05.005
30. Mahmood K, Zia KM, Zuber M, Salman M, Anjum MN. Ac ce p t e d u s i p t. *Int J Biol Macromol*. Published online 2015. doi:10.1016/j.ijbiomac.2015.09.026
31. Akahashi MAT, Echi SHU, Akara KET, Sikin YOA. Evaluation of an Oral Carrier System in Rats : Bioavailability and Antioxidant Properties of Liposome-Encapsulated Curcumin. Published online 2009:9141-9146. doi:10.1021/jf9013923
32. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations : a future nanomedicine for cancer. *Drug Discov Today*. 2012;17(1-2):71-80. doi:10.1016/j.drudis.2011.09.009
33. Baglolle KN, Boland PG, Wagner BD. Fluorescence enhancement of curcumin upon inclusion into parent and modified cyclodextrins. 2005;173:230-237. doi:10.1016/j.jphotochem.2005.04.002
34. Rasmussen HB, Christensen SB, Kvist LP, Karazmi A. A Simple and Efficient Separation of the Curcumins , the Antiprotozoal Constituents of *Curcuma longa*. 2000;66:396-398.
35. Allen PC, Danforth HD, Augustine PC. Dietary modulation of avian coccidiosis.
36. NII-Electronic Library Service.
37. Oide TK, Ose MN, Gihara YO, Abu YY, Hta NO. Leishmanicidal Effect of Curcumin in Vitro. 2002;25(January):131-133.
38. Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. 2005;326:472-474. doi:10.1016/j.bbrc.2004.11.051
39. Cui J, Yu B, Zhao Y, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. 2009;371:148-155. doi:10.1016/j.ijpharm.2008.12.009
40. Gao Y, Li Z, Sun M, et al. and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. 2010;36(10):1225-1234. doi:10.3109/03639041003695139
41. Ochar NIK, Garwal MAGA. Safety and Pharmacokinetics of a Solid Lipid Curcumin Particle Formulation in Osteosarcoma Patients and Healthy Volunteers. Published online 2010:2095-2099. doi:10.1021/jf9024807
42. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG / PCL diblock copolymeric micelles : a novel controlled delivery vehicle for cancer therapy. :433-449.
43. *The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease*.
44. Mukerjee A. Nanospheres for Cancer Therapy Formulation , Characterization and Evaluation of Curcumin-loaded PLGA Nanospheres for Cancer Therapy. 2014;(October 2009).
45. Bourne KZ, Bourne N, Reising SF, Stanberry LR. Plant products as topical microbicide candidates : assessment of in vitro and in vivo activity against herpes simplex virus type 2. 1999;42:219-226.
46. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A Review on Antibacterial , Antiviral , and Antifungal Activity of Curcumin. 2014;2014.
47. Jiang M, Lin J, Chen SS. Inhibition of HIV-1 Tat-Mediated Transactivation by Quinacrine and Chloroquine to induce the expression of HIV-1 structural proteins and thereby shifts the early phase of HIV-1 replication to the late cytopathic phase of the replication cycle (5). *Tat e*. 1996;7:1-7.
48. Artico M, Santo R Di, Costi R, et al. Geometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase : Synthesis , Biological Evaluation , and Molecular Modeling. 1998;2623(97):3948-3960.
49. Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E. Curcumin Analogs with Altered Potencies against HIV-1 Integrase as Probes for. 1997;2623(97):3057-3063.
50. Pardee B. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. 1993;90(March):1839-1842.
51. Burke TR, Fesen MR, Mazumder A, et al. Hydroxylated Aromatic Inhibitors of HIV- 1 Integrase. Published online 1995:4171-4178.
52. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer ' s disease animal models. 2004;6:367-377.
53. Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer ' s Disease. 2010;16:285-297. doi:10.1111/j.1755-5949.2010.00147.x
54. Tang M, Taghibiglou C. The Mechanisms of Action of Curcumin in Alzheimer ' s Disease. 2018;58(2017):1003-1016. doi:10.3233/JAD-170188
55. Science B. ATTENUATION OF RENAL FIBROSIS BY CURCUMIN IN RAT. Published online 2005.

doi:10.1016/j.urology.2005.09.028

56. Huang M, Ma W, Yen P, et al. Inhibitory effects of topical application of low doses of curcumin on 12- O - tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. 1997;18(1):83-88.
57. Chaudhary LR, Avioli L V. Regulation of Interleukin-8 Gene Expression by Interleukin-1 β , Osteotropic Hormones , and Protein Kinase Inhibitors in Normal Human Bone Marrow Stromal Cells *. 1996;271(28):16591-16596.
58. Gupta B, Ghosh B. Curcuma longa inhibits TNF- α induced expression of adhesion molecules on human umbilical vein endothelial cells. 1999;21:745-757.
59. Kang BY, Song YJ, Kim K, Choe YK, Hwang SY, Kim TS. Curcumin inhibits Th1 cytokine pro ® le in CD4 + T cells by suppressing interleukin-12 production in macrophages. Published online 1999:380-384.
60. Chen Y, Tan T. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Published online 1998.
61. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF- κ B activation via the NIK / IKK signalling complex. Published online 1999.
62. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage Migration Inhibitory Factor Up-regulates Expression of Matrix Metalloproteinases in Synovial Fibroblasts of Rheumatoid Arthritis *. 2000;275(1):444-450.
63. Universiteit V. compounds . The case of curcumin. 1996;26(7):667-680.
64. Morgan CJ, Haworth AE, Morgan CJ. domestic setting. Published online 2003:224-238.
65. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory Effect of Curcumin , a Food Spice from Turmeric , on Platelet-Activating Factor- and Arachidonic Acid-Mediated Platelet Aggregation through Inhibition of Thromboxane Formation and Ca ²⁺ Signaling. 1999;58(99):1167-1172.
66. Lao CD, Iv MTR, Normolle D, et al. BMC Complementary and Dose escalation of a curcuminoid formulation. 4:4-7. doi:10.1186/1472-6882-6-10
67. Das KC, Das CK. Curcumin (diferuloylmethane), a singlet oxygen (¹ O ₂) quencher. 2002;295:62-66.
68. Dhillon N, Aggarwal BB, Newman RA, et al. Cancer Therapy : Clinical Phase II T rial of Curcumin in Patients with Advanced Pancreatic Cancer. 2008;14(16):4491-4500. doi:10.1158/1078-0432.CCR-08-0024
69. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases : an age-old spice with modern targets. 2008;(December):85-94. doi:10.1016/j.tips.2008.11.002
70. Ojha H. Author ' s personal copy Analytical Methods Estimation of antiradical properties of antioxidants using DPPH[•] assay ...
71. Abe Y, U SHUH, Horie T. CURCUMIN INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION BY HUMAN PERIPHERAL BLOOD MONOCYTES AND. 1999;39(1):0-6.
72. Yu H, Huang Q. Enhanced in vitro anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. *Food Chem.* 2010;119(2):669-674. doi:10.1016/j.foodchem.2009.07.018
73. López-Iñzaro M. Review Anticancer and carcinogenic properties of curcumin : Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Published online 2008:103-127. doi:10.1002/mnfr.200700238
74. Ak T. Chemico-Biological Interactions Antioxidant and radical scavenging properties of curcumin. 2008;174:27-37. doi:10.1016/j.cbi.2008.05.003
75. Schaaf C, Shan B, Buchfelder M, et al. Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Published online 2009. doi:10.1677/ERC-09-0129